AWT-008 is under clinical development by Anwita Biosciences and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AWT-008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AWT-008 (JS-014) is under development for the treatment of solid tumors and lymphoma. The drug candidate is a recombinant IL-21 and anti human serum albumin (HAS) single domain nanobody fusion protein that acts by targeting interleukin 21 receptor. It is administered through intravenous route.
Anwita Biosciences overview
Anwita Biosciences is an emerging biopharmaceutical company. The company is specialized in the discovery and development of optimized immuno-therapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering. Anwita Biosciences is headquartered in San Carlos, California, the US.
For a complete picture of AWT-008’s drug-specific PTSR and LoA scores, buy the report here.